Global Pharma, Biotech and Diagnostics Distribution Partnering Terms and Agreements 2014-2020: Access the Listing of Over 1,700 Distribution Deals
DUBLIN, Oct. 21, 2020 /PRNewswire/ -- The "Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.
The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides fully revised and updated, the report provides details of distribution agreements from 2014 to 2020.
The report provides a detailed understanding and analysis of how and why companies enter distribution deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 1,700 distribution deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2014.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.
Report scope
- Trends in distribution dealmaking in the biopharma industry since 2014
- Analysis of distribution deal structure
- Case studies of real-life distribution deals
- Access to over 2,000 distribution deals documents
- The leading distribution deals by value since 2014
- Most active distribution dealmakers since 2014
- The leading distribution partnering resources
In Distribution Partnering Terms and Agreements, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
- Technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in distribution dealmaking
2.1. Introduction
2.2. Definition of distribution deals
2.3. Trends in distribution deals since 2014
2.3.1. Distribution dealmaking by year, 2014 to 2020
2.3.2. Distribution dealmaking by phase of development since 2014
2.3.3. Distribution dealmaking by industry sector since 2014
2.3.4. Distribution dealmaking by therapy area since 2014
2.3.5. Distribution dealmaking by technology type since 2014
2.3.6. Distribution dealmaking by most active company since 2014
2.3.7. Attributes of pure distribution deals
2.3.8. Attributes of distribution in multi-component deals
2.4. Aligning partners to make the distribution agreement work
Chapter 3 - Overview of distribution deal structure
3.1. Introduction
3.2. Distribution agreement structure
3.3. Example distribution agreements
3.3.1. Case study 1: Zeltiq Aesthetics - Advance Medical
3.3.2. Case study 2: QLT - ASD Speciality Healthcare
3.4 Distribution rights as part of a wider alliance agreement
3.4.1. Case study 1: Caleco Pharma - Natac Biotech
3.4.2. Case study 2: Purdue Pharma - Transcept Pharmaceuticals
Chapter 4 - Leading distribution deals
4.1. Introduction
4.2. Top distribution deals by value
Chapter 5 - Top 25 most active distribution dealmakers
5.1. Introduction
5.2. Top 25 most active distribution dealmakers
Chapter 6 - Distribution deals including contracts directory
6.1. Introduction
6.2. Distribution deals with contracts since 2014
Appendices
Appendix 1 - Distribution dealmaking by companies A-Z
Appendix 2 - Distribution dealmaking by industry sector
Appendix 3 - Distribution dealmaking by stage of development
Appendix 4 - Distribution dealmaking by therapy area
Appendix 5 - Distribution dealmaking by technology type
For more information about this report visit https://www.researchandmarkets.com/r/qq4e0d
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article